Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 41 | 1,078 | 411 | 1,226 | 2,190 | 4,153 | 4,537 | 6,409 |
| Operating profit | $m | 1,055 | 1,700 | ||||||
| Net profit | $m | -608 | -408 | -710 | -295 | 833 | 1,292 | 1,345 | 1,889 |
| EPS reported | $ | 19.63 | 20.82 | ||||||
| Operating cashflow per share | $ | 11.18 | 15.53 | ||||||
| Capex per share | $ | 0.10 | 0.06 | ||||||
| FCF per share | $ | 11.08 | 15.47 | ||||||
| Free cash flow | $m | 679 | 1,156 | ||||||
| Net debt | $m | -4,357 | -5,137 | ||||||
| Book value equity | $m | 7,323 | 8,417 | ||||||
| Book value per share | $ | 110.9 | 129.7 | ||||||
| Number of shares | m | 66.03 | 64.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 42.84 | - | ||||||
| P/B LTM | x | 7.04 | 6.92 | ||||||
| P/S LTM | x | 12.41 | 9.67 | ||||||
| P/FCF LTM | x | 75.91 | 50.37 | ||||||
| EV/EBITDA LTM | x | 36.72 | 31.96 | ||||||
| EV/Sales LTM | x | 11.59 | 8.81 | ||||||
| Earnings Yield LTM | % | 2.33% | 2.26% | ||||||
| FCF Yield | % | 1.32% | 1.99% | ||||||
| Quality | |||||||||
| ROE | % | 17.64% | 16.86% | ||||||
| ROIC | % | 14.30% | 13.96% | ||||||
| Operating margin | % | 25.39% | 29.35% | ||||||
| Gross margin | % | 89.15% | 90.49% | ||||||
| FCF/Sales | % | 16.35% | 21.67% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +53.60% | +170.04% | ||||||
| Sales Growth YoY | % | +89.64% | +156.47% | ||||||
| Net Income Growth YoY | % | +55.10% | +272.45% | ||||||
| FCF Growth | % | - | +144.05% | ||||||
| Operating Profit Growth | % | - | +380.08% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 8.13 | 24.59 | ||||||
| Net Debt/EBITDA | x | -2.60 | -2.55 | ||||||
| EBIT/Net interest | x | 258.36 | 443.95 | ||||||
| Net debt/market cap | % | -8.45% | -8.82% | ||||||
| Net debt/Equity | x | -0.59 | -0.61 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
ETFs that hold argenx
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 6 | 3.77% |
| First Trust NYSE Arca Biotechnology Index Fund | FBT | 7 | 3.80% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 8 | 3.10% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 8 | 2.97% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 8 | 3.09% |
| Dynamic Active Global Dividend ETF | DXG.TO | 5 | 4.49% |
| VanEck Biotech ETF | BBH | 6 | 4.51% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 8 | 3.11% |
| iShares MSCI Belgium ETF | EWK | 2 | 16.55% |
| Nomura Focused International Core ETF | EXUS | 9 | 3.23% |
Funds with argenx among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 6 | 3.77% |
| First Trust NYSE Arca Biotechnology Index Fund | FBT | 7 | 3.80% |
| iShares MSCI Europe Health Care Sector UCITS ETF | ESIH.DE | 8 | 3.10% |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE) | EXV4.DE | 8 | 2.97% |
| State Street SPDR MSCI Europe Health Care UCITS ETF | HLTH.L | 8 | 3.09% |
| Dynamic Active Global Dividend ETF | DXG.TO | 5 | 4.49% |
| VanEck Biotech ETF | BBH | 6 | 4.51% |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1C | DXSE.DE | 8 | 3.11% |
| iShares MSCI Belgium ETF | EWK | 2 | 16.55% |
| Nomura Focused International Core ETF | EXUS | 9 | 3.23% |
Funds with argenx among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free